Ingram Micro’s IT Channel Partners Gain an Advantage with “Core to Edge” Advanced Solutions for Securing and Managing the Distributed Enterprise
Ingram Micro Inc.’s multi-million-dollar investments within its global Advanced Solutions organization are resulting in new and innovative business resources, opportunities, services and solutions for IT channel partners in more than 122 countries. As part of its efforts, the industry leader is also continuing to modernize its processes and systems enabling channel partners to benefit from and provide a more exceptional customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005190/en/
Ingram Micro Inc.’s multi-million-dollar investments within its global Advanced Solutions organization are resulting in new and innovative business resources, opportunities, services and solutions for IT channel partners in more than 122 countries. (Photo: Business Wire)
“Our global Advanced Solutions organization continues to give our channel partners a clear advantage in the markets they serve locally and globally,” says Paul Bay, executive vice president and president, Global Technology Solutions, Ingram Micro. “We’re continuing to invest in and serve as a business partner to solution providers, as well as Managed Services and cloud providers, giving them more innovative ways to run their businesses better, grow markets faster and do more for their customers. We’ve also made it easier for technology manufacturers, cloud and software companies to have an efficient, high impact sales channel with multiple routes to market worldwide.”
Ingram Micro’s Advanced Solutions is a worldwide organization anchored by eight global Centers of Excellence (COEs) and thousands of specialists and solutions architects spanning 122 countries. The worldwide business engages with more than 180 emerging and established vendor partners and operates throughout Asia Pacific (APAC), North America, Latin America, Europe, Middle East and Africa (EMEA).
Over the last three years, Ingram Micro’s Advanced Solutions organization enabled thousands of midsized and small business channel partners to offer a variety of technology solutions including Artificial Intelligence, Cloud, Data Center, IoT, Security and UCaaS technologies. And, within the last 18 months, the organization has achieved major milestones including:
- Established an innovative Ingram Micro Financial Solutions’ global team ready to design ways to boost cashflow by allowing businesses to buy cloud and consumption licenses together with technology product to consume technology as an operating expense, and an agile credit organization granting auto-credit increases for loyal Ingram Micro channel partners.
- A custom program for new and emerging manufacturers or providers of enterprise-grade technology solutions and services, such as its most recent global announcement with UiPath
- Record growth of nearly 30% with Cybersecurity solutions from more than 80 providers and IT channel ecosystem partners, including the industry’s most valuable Cybersecurity companies, and groundbreaking Ingram Micro software solutions currently under pilot in EMEA.
- Additions to the Business Transformation Centers in Buffalo, NY and recently launched Center in Singapore, showcasing exclusive Ingram Micro-bundled Advanced Solutions, which include in-house consultative professional experts and services, in addition to proof-of-concept demonstrations for business decision-makers.
- Debut of the UCC Center of Excellence in EMEA, which served as a lifeline for channel partners across EMEA supplying Unified Communications and UCaaS during the pandemic.
- Expanded Data Center Managed and Professional Services, which give channel partners an easier way to market, sell and support a full solution stack on premise, hybrid and in the cloud.
- Launch of Ingram Micro’s IoT Innovation Lab and Virtual Experience team based in Irvine, CA, providing a fast-track to IoT solutions adopted by local governments, healthcare, and manufacturing.
- Dozens of industry accolades locally, regionally and globally for its excellence in execution including Distributor of the Year and Partner of the Year in 2020 and 2021.
“Last quarter we had a number of strategic vendors sign new agreements in Latin America, North America and APAC to ensure channel partners have an expert level of support for their solutions,” says Advanced Solutions leader Sabine Howest, vice president, Global Partner Engagement and IoT, Ingram Micro.
Additionally, new investments are being made to enhance Ingram Micro’s expertise across the board and in specific categories including robotics and automation, as well as IoT and Artificial Intelligence.
“We’re assembling an ecosystem of valuable partnerships, combined with experts only Ingram Micro can provide to make it easier for our channel partners to go-to-market in a more agile way with modern technology solutions,” says Howest. “More and more channel partners and providers are using our COEs to build unique, global go-to-market teams and alliances to support their solutions and services. 2020 brought us closer to our partners and providers, together we grew stronger and accomplished more than we ever imagined. This year we’ve set the bar high to invest in our partners and give them an even stronger advantage.”
For more information, Ingram Micro channel partners are encouraged to connect with their sales representatives. Click here to learn more about Ingram Micro Advanced Solutions.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Marie Meoli Rourke
WhiteFox Marketing Inc.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release
Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),
New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an
Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release
Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As
Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release
The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,
Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release
Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting11.6.2021 09:05:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients,with follow-up of at least 3 months, and ranging from 4 months to 26 months, treated with the investigational CRISPR/Cas9-based gene-editing therapy, CTX001, that show a consistent and sustained response to treatment. CTX001 is being investigated in two ongoing Phase 1/2 clinical trials as a potential one-time therapy for patients suffering from transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). In total, more than 40 patients have been dosed across both studies to date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005069/en/ All 15 patients with TDT, including six who have the beta zero/beta zero or other severe genotypes, were transfusion-free at last follow-up, and all seven patients with severe SCD were free of vaso-occlusive crises (VOCs) from CTX001 infu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom